Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 1
1991 1
1992 2
1993 2
1996 6
1997 3
1998 4
1999 6
2000 8
2001 8
2002 14
2003 11
2004 13
2005 17
2006 5
2007 4
2008 9
2009 6
2010 13
2011 18
2012 10
2013 22
2014 12
2015 17
2016 13
2017 8
2018 18
2019 8
2020 23
2021 20
2022 16
2023 12
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

300 results

Results by year

Filters applied: . Clear all
Page 1
A hard truth to swallow: critically evaluating the MD Anderson Dysphagia Inventory (MDADI) as an endpoint in human papillomavirus-associated oropharyngeal cancer trials.
McDowell L, King MT, Hutcheson KA, Ringash J, Yom SS, Corry J, Henson C, Mehanna H, Rischin D. McDowell L, et al. Among authors: rischin d. Int J Radiat Oncol Biol Phys. 2024 May 11:S0360-3016(24)00628-X. doi: 10.1016/j.ijrobp.2024.05.005. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38740309 Review.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Among authors: rischin d. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Rischin D, Hughes BGM, Basset-Séguin N, Schadendorf D, Bowyer S, Trabelsi Messai S, Meier F, Eigentler TK, Casado Echarren V, Stein B, Beylot-Barry M, Dalac S, Dréno B, Migden MR, Hauschild A, Schmults CD, Lim AM, Yoo SY, Paccaly AJ, Papachristos A, Nguyen JH, Okoye E, Seebach F, Booth J, Lowy I, Fury MG, Guminski A. Rischin D, et al. J Immunother Cancer. 2024 Mar 11;12(3):e008325. doi: 10.1136/jitc-2023-008325. J Immunother Cancer. 2024. PMID: 38471711 Free PMC article. Clinical Trial.
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
McLean LS, Lim AM, Bressel M, Lee J, Ladwa R, Guminski AD, Hughes B, Bowyer S, Briscoe K, Harris S, Kukard C, Zielinski R, Alamgeer M, Carlino M, Mo J, Park JJ, Khattak MA, Day F, Rischin D. McLean LS, et al. Among authors: rischin d. Med J Aust. 2024 Feb 5;220(2):80-90. doi: 10.5694/mja2.52199. Epub 2024 Jan 11. Med J Aust. 2024. PMID: 38212673
300 results